Key result
Beta-blocker therapy provides well-established benefits for patients with acute myocardial infarction, but this benefit diminishes over time and is not strong in the perioperative setting.
Why the study?
To better understand beta-adrenoceptor antagonist use in patients with acute coronary syndrome, stable coronary heart disease, and in the perioperative setting.
Does beta-blocker therapy improve outcomes in patients with acute coronary syndrome, stable coronary heart disease, and in the perioperative setting?
Does beta-blocker therapy improve outcomes in patients with acute coronary syndrome, stable coronary heart disease, and in the perioperative setting?
Beta-blockers have well-established benefits in acute myocardial infarction, but their long-term efficacy and utility in the perioperative setting are less robust.
Short-term post-MI beta-blocker use remains supported while long-term continuation warrants reevaluation; extends time-dependent efficacy data from prior trials.
Coronary artery disease (CAD) is the most prevalent cardiovascular disease characterized by atherosclerotic plaque buildup that can lead to partial or full obstruction of blood flow in the coronary arteries. Treatment for CAD involves a combination of lifestyle changes, pharmacologic therapy, and modern revascularization procedures. Beta-adrenoceptor antagonists (or beta-blockers) have been widely used for decades as a key therapy for CAD. In this review, prior studies are examined to better understand beta-adrenoceptor antagonist use in patients with acute coronary syndrome, stable coronary heart disease, and in the perioperative setting. The evidence for the benefit of beta-blocker therapy is well established for patients with acute myocardial infarction, but it diminishes as the time from the index cardiac event elapses. The evidence for benefit in the perioperative setting is not strong.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2023) conducted a review in Coronary artery disease. Beta-blockers was evaluated. Beta-blocker therapy provides well-established benefits for patients with acute myocardial infarction, but this benefit diminishes over time and is not strong in the perioperative setting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: